chrisvoncsefalvay/vaers-outcomes huggingface dataset:
itchiness around my chest and back then random areas on my body; feel like bugs were crawling on me; more of a tingle; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38 year-old female patient received bnt162b2 (BNT162B2), administration date 15Sep2021 (Lot number: FC3184) at the age of 38 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PRURITUS (non-serious) with onset 2021, outcome "not recovered", described as "itchiness around my chest and back then random areas on my body"; FEELING ABNORMAL (non-serious) with onset 2021, outcome "not recovered", described as "feel like bugs were crawling on me"; PARAESTHESIA (non-serious) with onset 2021, outcome "not recovered", described as "more of a tingle". Therapeutic measures were not taken as a result of pruritus, feeling abnormal, paraesthesia.  Additional information: The patient did not have repeating node relevant medical history and concurrent conditions. There was not reported name of the drug and reaction was allergy. Active Drug substance names: Covid-19. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has not been tested for COVID-19.  Follow-up attempts are completed. No further information is expected.
under 18 years old, received the vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (under 18 years old, received the vaccine) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-May-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (under 18 years old, received the vaccine). On 28-May-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (under 18 years old, received the vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment information was not provided.
Pt. developed rash on 2/4/21, which resolved 2/7/2021.
2 days ago had a fine rash in diaper area and mother reports a sore on patients tongue.  The rash had small bumps scattered on legs by today (3 days).  Had slight fever.  Child acts fine, eating good and playing.
Panic attack; Heart racing; Hands cold; Sweating; This spontaneous case was reported by a patient and describes the occurrence of PANIC ATTACK (Panic attack), PALPITATIONS (Heart racing), PERIPHERAL COLDNESS (Hands cold) and HYPERHIDROSIS (Sweating) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ALBUTEROL SULFATE and HYDROXYZINE for an unknown indication.    On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jan-2021, the patient experienced PANIC ATTACK (Panic attack), PALPITATIONS (Heart racing), PERIPHERAL COLDNESS (Hands cold) and HYPERHIDROSIS (Sweating). At the time of the report, PANIC ATTACK (Panic attack), PALPITATIONS (Heart racing), PERIPHERAL COLDNESS (Hands cold) and HYPERHIDROSIS (Sweating) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Feb-2021, Blood test: normal (normal) normal. On 05-Feb-2021, Electrocardiogram: normal (normal) normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Had a low grade fever; Felt worn out; It really incapacitates me; When I had those low grade temps, my husband had to push me around in a wheelchair; Injection site itchy; It was only very slightly tender; This case was reported by a consumer and described the occurrence of multiple sclerosis exacerbation in a 66-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included multiple sclerosis and heat sensitivity.   On 18th October 2019, the patient received the 1st dose of Shingrix. In October 2019, less than a week after receiving Shingrix, the patient experienced multiple sclerosis exacerbation (serious criteria GSK medically significant), injection site itching, injection site tenderness and activities of daily living impaired. On 18th October 2019, the patient experienced low grade fever and worn out. The patient was treated with ibuprofen and paracetamol (Tylenol). On an unknown date, the outcome of the multiple sclerosis exacerbation, injection site itching, injection site tenderness, low grade fever, worn out and activities of daily living impaired were unknown.   It was unknown if the reporter considered the multiple sclerosis exacerbation, injection site itching, injection site tenderness, low grade fever, worn out and activities of daily living impaired to be related to Shingrix.  Additional details were provided as follows: The patient received the Shringrix vaccine on Friday. The patient was cautioned that the patient's arm would be extremely painful for 2 to 3 days afterwards.  The injection site was initially itchy, but after that the patient noticed no difference, unless pushed on the site and it was only very slightly tender.  It was reported that on the same day in the evening less than a day after vaccination and for 3 days afterward (and day before reporting) the patient had a low grade fever and patient felt worn out.  The patient had MS and therefore the patient was very sensitive to heat - fever or increased weather temperatures.  The patient could get around quite well with a walker, but when had those low grade temperatures, the patient's husband had to push her around in a wheelchair.  The patient reported that It really incapacitates her. The patient had been taking Ibuprofen and Tylenol and that seems to help. But she did not like to take too much of that due to liver/kidney concerns.
caused immune system to work overtime; suspected vaccination failure/had last shot, got shingles; shingles//had last shot, got shingles; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included COVID-19 VACCINE (COVID-19 BOOSTER) for prophylaxis.   The patient's past medical history included shingles (had shingles ).   In February 2022, the patient received Shingles vaccine. On an unknown date, the patient received COVID-19 BOOSTER. In June 2022, less than 5 months after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the patient experienced immune system disorder. On an unknown date, the outcome of the vaccination failure, shingles and immune system disorder were unknown.   It was unknown if the reporter considered the vaccination failure, shingles and immune system disorder to be related to Shingles vaccine.     Additional Information: GSK receipt date: 24-June-2022 Reporter's comment: The case was reported by the patient via interactive digital media. The patient had the last shot for shingles in February and 4 days ago the reporting date, the patient got shingles. The patient stated that going with it would be a lot worse then if the patient not had the vaccine, because it was not even one-fourth as bad as the patient had it the first time. After speaking with the physician, the patient believed that the Covid booster caused his/her immune system to work overtime (had major reaction) causing a shingles flair. The patient stated that the shingles was horrid. Additional supportive information: The reporter considered the shingles and immune system disorder to be related to Covid 19 booster. This case was considered as suspected vaccination failure since the details regarding the completion of primary vaccination schedule and laboratory confirmation of shingles were unknown at the time of reporting. The follow-up could not be possible as no contact details were available. Note: As it was unknown whether the patient had received the Covid booster before or after the Shingles vaccine and there is no contact details were available, therefore case was conservatively processed considering Covid booster as suspect product.
One of four pt's who were immun fr the same vial developed local rxn, size of a quarter or fifty cent coin; Site of inject was red, hot to touch & pt c/o tenderness;
chills; abdominal pain/stomach pains; is very tired; her arms became swollen; the arm where the vaccine was given was swollen and a bit sore and a bit painful; the arm where the vaccine was given was swollen and a bit sore and a bit painful; Pain is not as bad, but it is a really tight feeling; Fatigue; Rash; she had a big red, and painful round rash; area swollen, a bit sore, a bit painful/it's still somewhat swollen/swelling; area swollen, a bit sore, a bit painful/it's not quite as sore/soreness; This is a spontaneous report from a contactable consumer or other non-Health Care Professional.   A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: FL8982 and Expiry date: Unknown), dose 2 via an unspecified route of administration, administered in Arm Right on 09Feb2021 as DOSE 2, SINGLE for covid-19 immunization. The patient medical history was not reported. There were no concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the Covid vaccine. On an unspecified date the patient experienced her arms became swollen, chills, abdominal pain/stomach pains, the arm where the vaccine was given was swollen and a bit sore and a bit painful. On 09Feb2021 the patient experienced had a big red, and painful round rash, is very tired, area swollen, a bit sore, a bit painful/it's still somewhat swollen/swelling, on 10Feb2021 the patient experienced rash, on 11Feb2021 the patient experienced pain is not as bad, but it is a really tight feeling, fatigue. The outcome of events her arms became swollen, chills , abdominal pain/stomach pains , is very tired , the arm where the vaccine was given was swollen and a bit sore and a bit painful was unknown while the outcome of events she had a big red, and painful round rash, rash, area swollen, a bit sore, a bit painful/it's still somewhat swollen/swelling, area swollen, a bit sore, a bit painful/it's not quite as sore/soreness, pain is not as bad, but it is a really tight feeling , fatigue was not recovered.  Follow-up attempts completed. No further information expected.
Discharge Provider:  DO Primary Care Provider:  DO Admission Date: 8/31/2023 Discharge Date: 9/3/2023  DETAILS OF HOSPITAL STAY:   Clinical Narrative: 84 y/o F admitted for COVID 19+ infection with intractable symptoms with inability to care for herself.  She had hypoxia early on in the admission and has been on room air for several days.  She was given Remdesivir until 9/2.  She was seen by PT, OT and became stronger.  Patient was going to be discharged home on 9/2, but her transaminases increased.  Her Remdesivir was held the day of discharge, but her labs drawn prior to holding the medication were improved.  She didn't require any home oxygen.  She declined HHC services.     She will have repeat labs in 4 days and follow up with her PCP in a week.     Patient was admitted with sepsis on admission which resolved prior to discharge.     Thank you for the privilege of taking care of this nice lady.
Information has been received on 25-APR-2017 from a medical assistant regarding an unspecified number of patients of unknown ages and gender. The patients' concurrent conditions, medical history and concomitant medications were not reported. From 13-APR-2017 through 25-APR-2017, an unspecified number of patients were vaccinated with doses of PROQUAD lot # M043306, expiration 24-APR-2018 and lot # M042502, expiration 17-APR-2018 subcutaneous for prophylaxis which were improperly stored. Other suspect therapy included sterile diluent lot # M034763 expiration 22-APR-2019. The vaccines were stored between 6 degrees Fahrenheit and 14 degrees Fahrenheit for 4 hours and 14 minutes. There was no previous temperature excursion. The call was not made due to a data logger. The medical assistant confirmed that the sterile diluent used to reconstitute the PROQUAD was not improperly stored. No adverse effects were reported. No further information was reported. Follow up information was received from the medical assistant on 17-MAY-2017, referring to a 4 year old male patient. The patient administered the vaccine on 14-APR-2017. The medical assistant reported that they did not exactly know what caused the temperature excursion in April 2017, but they were thinking the door to the refrigerator might have been left slightly open. There had been no temperature excursions since that time. All telephone attempts to obtain follow-up information on 17-MAY-2017 had been unsuccessful. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1704USA013406: US-009507513-1705USA014055: US-009507513-1705USA014057: US-009507513-1705USA014058: US-009507513-1705USA014059: US-009507513-1705USA014060: US-009507513-1705USA014061: US-009507513-1705USA014062: US-009507513-1705USA014063: US-009507513-1705USA014064: US-009507513-1705USA014065: US-009507513-1705USA014066: US-009507513-1705USA014067: US-009507513-1705USA014068.
shingles outbreak from nect to breast area; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 72-year-old female patient who received Herpes zoster (Shingrix) (batch number 4LP5Y, expiry date 27th February 2021) for prophylaxis.   On 30th November 2018, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, 7 days after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The patient received of Shingrix and one week later was diagnosed with Shingles outbreak from neck to breast area.
Rash of pencil lead sized pink spots that started on his face/neck and spread over his torso and bottom.  Spots were light pink, some slightly raised, and paled when pressed. Also, hard red spot at sight of injection (front of thigh).
Small fiber neuropathy  Burst dose of predisone - 9 days - symptoms resolved when taking but returned a couple days later Celecoxib 100 mg - 2 daily for 2 weeks - symptoms resolved while taking but returned a few days later
I received an IM Fluarix Quadrivalent shot and there was much pain (6 out of 10 scale) in the right arm after administration. I developed a headache for 72 hours after the shot that went away; however, the pain (down to 3 out of 10) in my arm was continued for several weeks and interestingly I also felt pain in my left arm after 1 week of administration. Not sure why. It has been about 2 months and I feel muscle weakness and pain (currently 2 out of 10) in my right arm still. Not sure why this is continuing after the receiving the flu shot.
Reported feeling tired, making a chewing like motion with mouth.  Stated mouth really dry.
shortness of breath, chest pain, altered mental status, weakness, hallucinations, admit to hospital and discharged on 4/2
Patient developed rash along waistline. Pt went to the dermatologist and was told it was shingles.
Moderate sore arm; Took two naps; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Moderate sore arm) and SOMNOLENCE (Took two naps) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20-2A) for COVID-19 vaccination.     No Medical History information was reported.   On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 2 dosage form. On 28-Jan-2021, the patient experienced MYALGIA (Moderate sore arm) and SOMNOLENCE (Took two naps). At the time of the report, MYALGIA (Moderate sore arm) and SOMNOLENCE (Took two naps) outcome was unknown.            Concomitant medication use was unknown Treatment information was unknown   This case was linked to MOD-2021-307983, MOD-2021-308023 (Patient Link).
Patient admitted on 03/25/2021 through the emergency department for complaint of shortness of breath she was a resident of a Nursing Facility. Her oxygen  saturations were into 80%. Patient was poor historian her daughter at the bedside provided most history. Patient with recent admissions for coronavirus on 03/03/2021 and then again on 03/05/2021 for post coronavirus pneumonia. Throughout hospitalization patient with poor appetite, on 03/28/2021 noted to be somnolent, additional blood cultures and labs checked. Patient continue to decline, refused medications. Minimal responsiveness on 04/01/2021. Had episode of PAF on 4/1/21, renal dosed Eliquis per Cardiology. Service discussed with family multiple times about code status, he continued to be on decided home willing to change code status. Patient remained on high-flow oxygen and not eating. Patient very anxious increase work of breathing.  Patient died on 04/03/2021.
Besides flu like symptoms beginning 12 hours after injection and lasting 24-30 hrs, i woke up with a very swollen lymph node in pectoral/underarm area 48 hrs after injection. Dr ordered ultrasound of site. Determined 2 lymph nodes were enlarged. Prescribed cephalexin 500 mg 2 times a day for 10 days, ibuprofen and warm compresses. After 48 hours on antibiotics has slightly gone down in size.
Pt developed the following symptoms within 24 hours: fever x 2-3 days, knots at injection sites, URI symptoms with croupy cough, sensory issues- hypertonicity, didn't want water to touch him.
On Friday, March 19 around 9:10am I had seizures - loss of awareness, very pale, shaking (but not quite convulsions). This happened before 25 years ago and is likely unrelated to the vaccine. Expected cold/flu-like symptoms did occur on March 14 and part of March 15 but things have been fine since then. I've followed up with my GCP and am scheduling a Neuro appointment for followup.
This case was reported by a consumer and described the occurrence of injection site soreness in a 42-year-old female subject who was vaccinated with Fluarix (GlaxoSmithKline) for prophylaxis. A physician or other healthcare professional has not verified this report. Concurrent medications included Ibuprofen. On 8 October 2007 at 09:30 the subject received unspecified dose of Fluarix (.5 ml, unknown, left arm) On 8 October 2007, less than one day after vaccination with Fluarix, the subject experienced injection site soreness. She also reported that she was not able to raise her arm over her head. The consumer reported that she consulted a healthcare professional regarding the event. Medical attention was not required. The reporter noted that the events went away for a few days but returned. The reporter also questioned if there were other reports involving this lot number. The consumer considered that the events were disabling. At the time of reporting the event was unresolved.
Woke up morning after, heart racing and nausea. Later in the day noticed swollen lymphnode in armpit and painful
Pt w/known COVID exposure (7/20) p/w worsening sxs to urgent care on 7/23 and tested positive. After evaluation, was sent home w/plans to receive convalescent plasma as outpt (first dose given 7/28). After returning home p/t MMC ED w/worsening dyspnea despite having had Pfizer vaccinations on 3/11 & 3/31 and a single dose of convalescent plasma (7/28). Was admitted for additional management of acute hypoxic respiratory failure secondary to COVID19 viral PNA. He was given dexamethasone, tocilizumab and additional O2. Pt continues to require ICU level of care and continues to desat w/movement.  He will continue to be monitored closely for symptom resolution.
C/o itching around her mouth approx 10 min after receiving 1st flu vaccine BENADRYL 50 mg and ZANTAC 150 mg given PO - s/s improved within 30 min.
Patient felt dizzy and nauseous and so weak and she said she feels like she is passing out , her throat was not closed but kind of inflamed
Patient reports headache,  dizziness, feeling a hot sensation and a dry throat within 5 minutes after vaccine.  Patient had similar reaction for first dose. Patient received a medical consult and was approved for 2nd dose of Moderna. Patient reports no shortness of breath, no chest pain, no blurred vision.  Vitals taken at 2:04pm: blood pressure:110/76, pulse: 64 and oxygen: 96%.  At 2:09pm patients vitals are taken again blood pressure: 110/71, oxygen: 98% and pulse 60. Patient reports feeling no improvement. PHN offers to call 911 but patient declines request. At 2:15pm vitals are pulse: 67, blood pressure: 111/69 and oxygen:98%. Patient alert and oriented x 4. no new symptoms reported.  At 2:20pm patient reports dry throat is improving and heat sensation is improving . Vitals are pulse:62, oxygen:96% blood pressure:110/80. Patients' dizziness slowly improves . Headache resolves completely at 2:47pm.  Patient attempts to stand up but still feels slight dizziness. Patient wait 15 more minutes and is walked out accompanied by 2 PHNs to vehicle. Patient is told it is not safe to drive while dizzy and provided with ER precautions.
Patient states night after receiving vaccine she noticed intense itching/rash/red bumps on the backs of both hands. The next day it seemed to spread up to a little past the wrists and she also noticed the same red bumps around her mouth. She states no recent exposure to any other irritants that she can recall.
CLINICAL IMPRESSION 1. Pneumonia due to COVID-19 virus  2. Acute pulmonary embolism without acute cor pulmonale, unspecified pulmonary embolism type  3. Generalized weakness  4. Elevated troponin  5. Acute renal failure superimposed on stage 3b chronic kidney disease, unspecified acute renal failure type  6. Hypokalemia
shortness of breath; increased heart rate; burning sensation that went down his waist (lower part of his back), hot burning sensation that started from a small part of his body and went up to the top of his head; hot burning sensation that started from a small part of his body and went up to the top of his head; profuse sweating; This is a spontaneous report from a contactable consumer or other non hcp.   A 31-years-old male patient received bnt162b2 (BNT162B2 Solution for injection), dose 1 via an unspecified route of administration on 2021 (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunisation (31-years at the age of vaccination). The patient medical history was not reported.  The patient's concomitant medications were not reported.  The patient experienced shortness of breath, increased heart rate, burning sensation that went down his waist, hot burning sensation that started from a small part of his body and went up to the top of his head, hot burning sensation that started from a small part of his body and went up to the top of his head and profuse sweating on 2021 (Unspecified date). The outcome of the events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.